{"entity":{"id":"paper-papmet-pal-lancet-2021","kind":"paper","name":"PAPMET (SWOG 1500): cabozantinib versus sunitinib for metastatic papillary renal cell carcinoma","aka":[],"tldr":"In the first randomised trial to show a benefit in papillary kidney cancer, the MET-targeting kinase inhibitor cabozantinib delayed progression and tripled the response rate compared with sunitinib, while two other MET inhibitors did not.","summary":"Randomised phase 2 trial of 147 patients with metastatic papillary renal cell carcinoma randomised to sunitinib, cabozantinib, crizotinib or savolitinib; the crizotinib and savolitinib arms closed early for futility.\n\nMedian progression-free survival was 9.0 months with cabozantinib against 5.6 months with sunitinib (hazard ratio 0.60) and response 23 versus 4 percent.","asOf":"2026-09-17","links":[{"label":"Lancet 2021","url":"https://doi.org/10.1016/S0140-6736(21)00152-5"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/33592176/"}],"tags":[],"related":[],"cancers":["papillary-rcc"],"sections":[],"technologies":[],"targets":[],"drugs":["cabozantinib","crizotinib","savolitinib","sunitinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["papmet"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["lancet"],"dependsOn":[],"notes":[],"journal":"The Lancet","year":2021,"doi":"10.1016/S0140-6736(21)00152-5","pmid":"33592176","authors":"Pal SK, Tangen C, Thompson IM, et al.","paperType":"rct","findings":["Median progression-free survival 9.0 vs 5.6 months; hazard ratio 0.60.","Objective response 23 percent vs 4 percent."],"whatItMeans":"Cabozantinib is the preferred first-line targeted therapy for metastatic papillary renal cell carcinoma; immunotherapy combinations are being tested on top of it.","caveats":["Small phase 2 with unselected MET status.","Savolitinib may still have a role in MET-driven tumours."],"changedPractice":true,"participants":147},"route":"/key-papers/paper-papmet-pal-lancet-2021/","neighbours":{"cancer":[{"id":"papillary-rcc","kind":"cancer","name":"Papillary renal cell carcinoma","route":"/cancers/papillary-rcc/"}],"drug":[{"id":"cabozantinib","kind":"drug","name":"Cabozantinib","route":"/drugs/cabozantinib/"},{"id":"crizotinib","kind":"drug","name":"Crizotinib","route":"/drugs/crizotinib/"},{"id":"savolitinib","kind":"drug","name":"Savolitinib","route":"/drugs/savolitinib/"},{"id":"sunitinib","kind":"drug","name":"Sunitinib","route":"/drugs/sunitinib/"}],"trial":[{"id":"papmet","kind":"trial","name":"PAPMET (SWOG S1500)","route":"/trials/papmet/"}],"journal":[{"id":"lancet","kind":"journal","name":"The Lancet","route":"/journals/lancet/"}]}}